• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)

    10/30/24 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024.

    InMode Logo

    Third Quarter 2024 Highlights:

    • Quarterly GAAP revenue of $130.2 million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024).
    • Quarterly revenues from consumables and service of $15.8 million, a decrease of 11% compared to the third quarter of 2023.
    • GAAP operation income of $48.2 million, *non-GAAP operation income of $52.2 million.
    • Total cash position of $684.9 million as of September 30, 2024, including cash and cash equivalents, marketable securities, and short-term bank deposits.
    • Full-year 2024 revenue guidance has been revised to be between $410 million and $420 million, compared to prior guidance of $430 million to $440 million.

     

    U.S. GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q3 2024

    Q3 2023

    Q1-Q3 2024

    Q1-Q3 2023

    Revenues

    $130,232

    $123,112

    296,965

    365,267

    Gross Margins

    82 %

    84 %

    81 %

    83 %

    Net Income

    $50,990

    $46,520

    98,504

    142,754

    Earnings per Diluted Share

    $0.65

    $0.54

    1.19

    1.66

    *Non-GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q3 2024

    Q3 2023

    Q1-Q3 2024

    Q1-Q3 2023

    Gross Margins

    82 %

    84 %

    81 %

    84 %

    Net Income

    $54,971

    $53,084

    111,626

    160,032

    Earnings per Diluted Share

    $0.70

    $0.61

    1.34

    1.86

     

    *Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation adjustments.

    Management Comments

    "The third quarter presented ongoing challenges for InMode," said Moshe Mizrahy, Chief Executive Officer. "Macroeconomic conditions led to a decrease in demand for our consumables and new platform sales, while the launch of our latest platforms required extended adjustments to our production lines. Nevertheless, we believe our recent management changes will better align our operations with our strategic plan. We also take pride in our dedicated employees, whose hard work has allowed us to make faster-than-expected progress in fulfilling pre-orders."

    Third Quarter 2024 Financial Results

    Total GAAP revenues for the third quarter of 2024 reached $130.2 million (including $31.9 million in revenue from first half of 2024 pre-orders), an increase of 5.8% compared to $123.1 million in the third quarter of 2023.

    "Despite continued headwinds in the third quarter, we are pleased to have fulfilled our pre-orders ahead of schedule, allowing us to focus on execution once market demand recovers," said Yair Malca, Chief Financial Officer.

    GAAP and *non-GAAP gross margin for the third quarter of 2024 was 82% compared to a gross margin of 84% for the third quarter of 2023.

    GAAP operating margin for the third quarter of 2024 was 37%, compared to an operating margin of 38% in the third quarter of 2023. *Non-GAAP operating margin for the third quarter of 2024 was 40% compared to 43% for the third quarter of 2023. This decrease was primarily attributable to higher sales and marketing expenses, primarily driven by our recent management changes costs, higher commissions, as well as additional investments in trade shows and workshop activities.

    InMode reported GAAP net income of $51.0 million, or $0.65 per diluted share, in the third quarter of 2024, compared to $46.5 million, or $0.54 per diluted share, in the third quarter of 2023. On a *non-GAAP basis, InMode reported net income of $55.0 million, or $0.70 per diluted share, in the third quarter of 2024, compared to $53.1 million, or $0.61 per diluted share, in the third quarter of 2023.

    2024 Financial Outlook

    Management provided an outlook for the full year of 2024 ending December 31, 2024. Based on our current estimates, management expects:

    • Full Year 2024 revenue to be between $410 to $420 million compared to prior guidance of $430 million to $440 million
    • *Non-GAAP gross margin between 81% and 82% compared to prior guidance of 82% - 84%
    • *Non-GAAP income from operations to be between $140 million and $145 million compared to prior guidance of $150 million to $155 million
    • *Non-GAAP earnings per diluted share remains the same as in previous guidance at $1.92 to $1.96 after taking into consideration the estimated shares that will be repurchased as part of the share repurchase programs announced this year

    This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. See "Forward-Looking Statements" for additional information.

    *Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation adjustments.

    The Current Situation in Israel

    Regarding the current situation in Israel, management would like to assure investors that the Company is prioritizing the safety and well-being of its employees, and all its team are safe. However, an inability to promptly receive needed supplies and materials due to the ongoing and unpredictable nature of the conflict in Israel and the surrounding region may adversely impact our ability to commercialize and manufacture our product candidates and products in a timely manner. This could cause several delays and/or issues for our operations, which in turn would have a material adverse impact on our ability to commercialize our product candidates and our financial condition.

    Use of Non-GAAP Financial Measures

    In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.

    Conference Call Information

    Mr. Moshe Mizrahy, Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer and Mr. Yair Malca, Chief Financial Officer, will host a conference call today, October 30, 2024, at 8:30 a.m. Eastern Time to discuss the third quarter 2024 financial results.

    The Company encourages participants to pre-register for the conference call using the following link: 

    https://dpregister.com/sreg/10193479/fdae439271.

    Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

    For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

    U.S. Toll-Free Dial-in Number: 1-833-316-0562

    Israel Toll- Free Dial-in Number: 1-80-921-2373

    International Dial-in Number: 1-412-317-5736

    Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=X3HVujVC

    At:

    8:30 a.m. Eastern Time

    5:30 a.m. Pacific Time

    The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from October 30, 2024, at 12 p.m. Eastern Time to November 13, 2024, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: 

    Replay Dial-in U.S. TOLL-FREE: 1-877-344-7529

    Replay Dial-in Canada TOLL-FREE: 855-669-9658

    Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088

    Replay Pin Number: 5305602

    To access the replay using an international dial-in number, please select the link below:

    https://services.choruscall.com/ccforms/replay.html

    A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.

    About InMode

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

    Forward-Looking Statements 

    The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2024 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 13, 2024, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

    Company Contact:

    Yair Malca

    Chief Financial Officer

    Phone: (949) 305-0108

    Email: [email protected]

    Investor Relations Contact:

    Miri Segal

    MS-IR LLC

    Email: [email protected]

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    Three months ended

    September 30,

    Nine months ended

    September 30,



    2024

    2023

    2024

    2023



    REVENUES

    130,232

    123,112

    296,965

    365,267



    COST OF REVENUES

    24,055

    20,136

    57,536

    60,444



    GROSS PROFIT

    106,177

    102,976

    239,429

    304,823



    OPERATING EXPENSES:











    Research and development

    3,254

    3,268

    10,470

    9,937



    Sales and marketing

    51,863

    50,819

    136,713

    143,591



    General and administrative

    2,799

    2,479

    7,579

    6,879



    TOTAL OPERATING EXPENSES

    57,916

    56,566

    154,762

    160,407



    OPERATIONS INCOME

    48,261

    46,410

    84,667

    144,416



    Finance income, net

    9,918

    4,953

    26,592

    12,687



    INCOME BEFORE INCOME TAXES

    58,179

    51,363

    111,259

    157,103



    INCOME TAXES

    7,189

    4,843

    12,755

    14,349



    NET INCOME

    50,990

    46,520

    98,504

    142,754















    EARNINGS PER SHARE:











    Basic

    0.66

    0.56

    1.20

    1.71



    Diluted

    0.65

    0.54

    1.19

    1.66



    WEIGHTED AVERAGE NUMBER OF SHARES

    OUTSTANDING USED IN COMPUTATION OF

    EARNINGS PER SHARE (in thousands)











    Basic

    77,022

    83,703

    81,795

    83,423



    Diluted

    77,908

    85,970

    83,016

    85,814



     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)









    September 30,

    2024

    December 31,

    2023

    Assets





    CURRENT ASSETS:





    Cash and cash equivalents

    164,838

    144,411

    Marketable securities

    281,458

    373,647

    Short-term bank deposits

    238,592

    223,547

    Accounts receivable, net of allowance for credit losses

    40,777

    42,362

    Prepaid expense and other receivables

    24,447

    16,268

    Inventories

    58,284

    45,095

             TOTAL CURRENT ASSETS

    808,396

    845,330

        NON-CURRENT ASSETS:





    Accounts receivable, net of allowance for credit losses

    2,917

    3,670

    Deferred income tax asset

    1,048

    1,506

    Operating lease right-of-use assets

    8,636

    9,698

    Property and equipment, net

    2,336

    2,382

    Other investments

    700

    700

    TOTAL NON-CURRENT ASSETS

    15,637

    17,956

    TOTAL ASSETS

    824,033

    863,286

    Liabilities and shareholders' equity





    CURRENT LIABILITIES:





    Accounts payable

    14,313

    13,966

    Contract liabilities

    17,230

    10,923

    Other liabilities

    44,155

    39,247

    TOTAL CURRENT LIABILITIES

    75,698

    64,136

        NON-CURRENT LIABILITIES:





    Contract liabilities

    3,318

    3,766

    Other liabilities

    2,808

    1,399

    Operating lease liabilities

    5,317

    6,613

    TOTAL NON-CURRENT LIABILITIES

    11,443

    11,778

    TOTAL LIABILITIES

    87,141

    75,914







    TOTAL SHAREHOLDERS' EQUITY

    736,892

    787,372

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

    824,033

    863,286

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended

    September 30,

    Nine months ended

    September 30,



    2024

    2023

    2024

    2023



    CASH FLOWS FROM OPERATING ACTIVITIES:











    Net income

    50,990

    46,520

    98,504

    142,754



    Adjustments required to reconcile net income to net cash provided by operating activities:











    Depreciation and amortization

    138

    129

    480

    501



    Share-based compensation expenses

    3,981

    6,564

    13,122

    17,278



    Change in allowance for credit losses of trade receivable

    130

    426

    414

    665



    Loss on marketable securities, net

    29

    -

    170

    -



    Finance expenses (income), net

    3,863

    (527)

    (5,934)

    (3,236)



    Deferred income taxes

    35

    (216)

    (58)

    (154)



    Changes in operating assets and liabilities:











    Decrease (increase) in accounts receivable

    (2,570)

    (10,753)

    1,924

    (16,461)



    Increase in other receivables

    (860)

    (1,347)

    (7,577)

    (5,367)



    Increase in inventories

    (5,657)

    (1,421)

    (13,189)

    (92)



    Increase (decrease) in accounts payable

    (1,235)

    (962)

    347

    (3,909)



    Increase (decrease) in other liabilities

    11,722

    3,040

    6,160

    (12,792)



    Increase (decrease) in contract liabilities (current and non-current)

    (26,517)

    (9)

    5,859

    (3,630)



    Net cash provided by operating activities

    34,049

    41,444

    100,222

    115,557



    CASH FLOWS FROM INVESTING ACTIVITIES:











       Investment in short-term deposits

    (78,390)

    (138,140)

    (164,687)

    (166,140)



       Proceeds from short-term deposits

    138,140

    50,590

    151,640

    85,090



       Purchase of fixed assets

    (77)

    (149)

    (435)

    (684)



       Purchase of marketable securities

    (90,820)

    (60,588)

    (276,513)

    (192,707)



       Proceeds from sale of marketable securities

    22,233

    -

    69,608

    -



       Proceeds from maturity of marketable securities

    122,969

    78,465

    304,777

    190,070



    Net cash provided by (used in) investing activities

    114,055

    (69,822)

    84,390

    (84,371)



    CASH FLOWS FROM FINANCING ACTIVITIES:











      Repurchase of ordinary shares

    (76,556)

    -

    (165,536)

    -



           Exercise of options

    565

    2,729

    1,194

    5,229



    Net cash provided by (used in) financing activities

    (75,991)

    2,729

    (164,342)

    5,229



    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS

    728

    (473)

    157

    (222)



    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

    72,841

    (26,122)

    20,427

    36,193















    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

    91,997

    159,855

    144,411

    97,540



    CASH AND CASH EQUIVALENTS AT END OF PERIOD

    164,838

    133,733

    164,838

    133,733



     

    Revision of prior period financial information

    The Company revised certain items within the investing activities with no impact on the net cash used in investing activities. The items impacted were "Investment in short-term deposits" and "Proceeds from short-term deposits" which were decreased by $41,000 and $119,000 for the three months and nine months ended September 30,2023 respectively and "Purchase of marketable securities" and "Proceeds from maturity of marketable securities" which were decreased by $0, and $40,423 for the three months and nine months ended September 30, 2023.

    These changes have no impact on our previously reported consolidated total cash flows from operating activities, financing activities and investing activities in the periods stated above as well as net income and net change in cash and cash equivalents.

    The Company evaluated the materiality of the adjustments, individually and in the aggregate, considering both qualitative and quantitative factors, and concluded that it was immaterial to the Company's prior periods' consolidated financial information. Since the revision was not material to any prior interim period or annual consolidated financial statements, no amendments to previously filed interim or annual periodic financial information was required. Consequently, the Company has revised the historical consolidated financial information presented herein for the impact of the above.

     

    INMODE LTD.

    CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)

     

     



    Three months ended September 30,

    Nine months ended September 30,

    2024

    2023

    2024

    2023

    Revenues by Category:



































    Capital Equipment revenues - United States

    85,734

    66 %

    67,969

    55 %

    151,392

    51 %

    191,548

    53 %

    Capital Equipment revenues - International

    28,662

    22 %

    37,276

    30 %

    86,191

    29 %

    114,284

    31 %

    Total Capital Equipment revenues

    114,396

    88 %

    105,245

    85 %

    237,583

    80 %

    305,832

    84 %

    Consumables and service revenues

    15,836

    12 %

    17,867

    15 %

    59,382

    20 %

    59,435

    16 %

    Total Revenue

    130,232

    100 %

    123,112

    100 %

    296,965

    100 %

    365,267

    100 %

























     

     



    Three months ended September 30,

    Nine months ended September 30,

    2024

    2023

    2024

    2023



    %

    %

    %

    %



    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    Revenues by Technology:

























    Minimal-Invasive

    95

    77

    90

    85

    80

    83

    90

    82

    88

    87

    76

    83

    Hands-Free

    4

    3

    4

    11

    4

    9

    7

    3

    5

    10

    5

    8

    Non-Invasive

    1

    20

    6

    4

    16

    8

    3

    15

    7

    3

    19

    9



    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

     

     

    INMODE LTD.

    RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF

     INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME 

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)









     

    Three months ended September 30, 2024

     

    Three months ended September 30, 2023



     

     

     

    GAAP

     

     

    Share Based

    Compensation

     

     

     

    Non-GAAP

     

     

     

    GAAP

     

     

    Share Based

    Compensation

     

     

     

    Non-GAAP



    REVENUES

    130,232

    -

    130,232

    123,112

    -

    123,112



    COST OF REVENUES

    24,055

    (481)

    23,574

    20,136

    (572)

    19,564



    GROSS PROFIT

    106,177

    481

    106,658

    102,976

    572

    103,548



    OPERATING EXPENSES:















    Research and development

    3,254

    (890)

    2,364

    3,268

    (729)

    2,539



    Sales and marketing

    51,863

    (2,300)

    49,563

    50,819

    (4,787)

    46,032



    General and administrative

    2,799

    (310)

    2,489

    2,479

    (476)

    2,003



    TOTAL OPERATING

    EXPENSES

     

    57,916

     

    (3,500)

     

    54,416

     

    56,566

     

    (5,992)

    50,574



    OPERATIONS INCOME

    48,261

    3,981

    52,242

    46,410

    6,564

    52,974



    Finance income, net

     

    9,918

     

    -

     

    9,918

     

    4,953

     

    -

    4,953



    INCOME BEFORE INCOME TAXES

    58,179

    3,981

    62,160

    51,363

    6,564

    57,927



    INCOME TAXES

    7,189

    -

    7,189

    4,843

    -

    4,843



    NET INCOME

    50,990

    3,981

    54,971

    46,520

    6,564

    53,084



















    EARNINGS PER SHARE:















    Basic

     

    0.66



     

    0.71

     

    0.56



    0.63



    Diluted

    0.65



    0.70

    0.54



    0.61



    WEIGHTED AVERAGE NUMBER OF

    SHARES OUTSTANDING USED IN

    COMPUTATION OF EARNINGS PER

    SHARE (in thousands)















    Basic

    77,022



    77,022

    83,703



    83,703



    Diluted

    77,908



    78,548

    85,970



    86,333



     

     



    Nine months ended September 30, 2024

    Nine months ended September 30, 2023

    GAAP

    Share Based

    Compensation

    Non-GAAP

    GAAP

    Share Based

    Compensation

    Non-GAAP

    REVENUES

    296,965

    -

    296,965

    365,267

    -

    365,267

    COST OF REVENUES

    57,536

    (1,361)

    56,175

    60,444

    (1,473)

    58,971

    GROSS PROFIT

    239,429

    1,361

    240,790

    304,823

    1,473

    306,296

    OPERATING EXPENSES:













    Research and development

    10,470

    (1,877)

    8,593

    9,937

    (1,987)

    7,950

    Sales and marketing

    136,713

    (9,007)

    127,706

    143,591

    (12,556)

    131,035

    General and administrative

    7,579

    (877)

    6,702

    6,879

    (1,262)

    5,617

    TOTAL OPERATING

    EXPENSES

    154,762

    (11,761)

    143,001

    160,407

    (15,805)

     

    144,602

    OPERATIONS INCOME

    84,667

    13,122

    97,789

    144,416

    17,278

     

    161,694

    Finance income, net

    26,592

    -

    26,592

    12,687

    -

    12,687

    INCOME BEFORE INCOME TAXES

    111,259

    13,122

    124,381

    157,103

    17,278

    174,381

    INCOME TAXES

    12,755

    -

    12,755

    14,349

    -

    14,349

    NET INCOME

    98,504

    13,122

    111,626

    142,754

    17,278

    160,032















    EARNINGS PER

    SHARE:













    Basic

    1.20



    1.36

    1.71



    1.92

    Diluted

    1.19



    1.34

    1.66



    1.86

    WEIGHTED AVERAGE NUMBER OF

    SHARES OUTSTANDING USED IN

    COMPUTATION OF EARNINGS PER

    SHARE (in thousands)













    Basic

    81,795



    81,795

    83,423



    83,423

    Diluted

    83,016



    83,536

    85,814



    86,154

     

    Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/inmode-reports-third-quarter-2024-financial-results-quarterly-gaap-revenue-of-130-2-million-which-consists-of-98-3-million-of-net-sales-in-q3-and-31-9-million-of-pre-orders-from-the-first-half-of-2024-302290744.html

    SOURCE InMode Ltd.

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:09:10 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:06:52 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mizrahy Moshe

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:08:06 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2026 before the Nasdaq market opens on Wednesday, May 6, 2026. InMode is currently finalizing its financial results for the first quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

    4/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Present at the 25th Annual Needham Virtual Healthcare Conference

    YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026. The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 11:00 am Eastern Time on Monday, April 13, and a live webcast of the presentation can be accessed here. InMode will also hold virtual one-on-one investor meetings

    3/24/26 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Announces New Share Repurchase Program

    YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the Company's total shares outstanding, representing approximately 6.38 million ordinary shares. In 2025, the Company repurchased approximately $127.4 million of its outstanding ordinary shares through share repurchase programs. Despite a challenging macroeconomic environment, the Company continues to generate strong cash fl

    3/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    3/13/26 7:00:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    2/23/26 7:00:19 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 filed by InMode Ltd.

    S-8 - InMode Ltd. (0001742692) (Filer)

    2/10/26 7:38:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2026 before the Nasdaq market opens on Wednesday, May 6, 2026. InMode is currently finalizing its financial results for the first quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

    4/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

    YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights: Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024.Quarterly revenues from consumables and service of $21.5 million, an increase of 8% compared to the fourth quarter of 2024.GAAP operation income of $26 million, *non-GAAP operation income of $28.5 million.Total cash position of $555.3 million as of December 31, 2025, including cash and cash equivalents, marketable securiti

    2/10/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M

    Conference call to be held on Tuesday, February 10, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year of 2025 before the Nasdaq market opens on Tuesday, February 10, 2026. InMode is currently finalizing its financial results for the fourth quarter and full year of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and ot

    1/8/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care